Zim Laboratories Ltd

Zim Laboratories Ltd

Zim Laboratories Ltd has announced its Q1 FY27 earnings conference call transcript, highlighting its EU-GMP remediation process, revenue growth, and EBITDA margins. The company has completed the EU-GMP reinspection and is awaiting the final inspection report, with a comprehensive CAPA plan in place. The company remains confident in its ability to successfully complete the remediation process and unlock growth opportunities.

Zim Laboratories Ltd

Zim Laboratories Ltd has announced the outcome of its postal ballot, where two special resolutions were passed with a requisite majority. The resolutions relate to the revision in remuneration structure and payment of remuneration to Dr. Anwar Daud, Managing Director, and Mr. Zulfiquar Kamal, Whole-Time Director.

Zim Laboratories Ltd

Zim Laboratories Ltd has announced the outcome of its postal ballot, where two special resolutions were passed with a requisite majority. The resolutions relate to the revision in remuneration structure and payment of remuneration to Dr. Anwar Daud, Managing Director, and Mr. Zulfiquar Kamal, Whole-Time Director.

Zim Laboratories Ltd

Zim Laboratories Ltd has made the audio recording of its Q1 FY27 earnings conference call available on its website.

Zim Laboratories Ltd

Zim Laboratories Ltd has published its financial results for the quarter ended 30th June 2026, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were published in three newspapers on 7th August 2026.

Zim Laboratories Ltd

Zim Laboratories Ltd has released its Q1 FY27 earnings presentation, showing a 31.2% increase in total operating income to ₹942 Mn and a 40.0% decline in EBITDA to ₹34 Mn. The company's EBITDA margin decreased by 430 bps to 3.7%. R&D spend increased to ₹82 Mn, with ₹34 Mn allocated towards BE studies and regulatory filings. The company has made progress on its EU-GMP CAPA remediation plan, with most of the plan completed and implemented.

Zim Laboratories Ltd

Zim Laboratories Ltd has announced its unaudited financial results for the quarter ended 30th June 2026, with revenue from operations at Rs. 9,417.85 lakhs and total income at Rs. 9,517.08 lakhs.

Zim Laboratories Ltd

Zim Laboratories Ltd has announced its unaudited financial results for the quarter ended 30th June 2026, with revenue from operations at Rs. 9,417.85 lakhs and total income at Rs. 9,517.08 lakhs.

Zim Laboratories Ltd

Zim Laboratories Ltd has announced the schedule for its Q1FY27 Earnings Conference Call, to be held on August 7th, 2026, at 12:00 PM IST.

Zim Laboratories Ltd

Zim Laboratories Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 06/08/2026 to consider and approve Unaudited Financial Results for the quarter ended 30th June, 2026.

Zim Laboratories Ltd

Zim Laboratories Ltd has announced the transfer of shares to IEPF Authority, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has published a notice in newspapers regarding the transfer of equity shares to the IEPF Account. The financial results for the quarter ended June 30, 2026, have been made available on the stock exchange website and the company's website.